<DOC>
	<DOCNO>NCT02194803</DOCNO>
	<brief_summary>A multicentre , open-label , non-interventional study observe treatment pattern patient wet age-related macular degeneration ( wAMD ) , visual impairment due diabetic macular edema ( DME ) , due macular edema follow retinal vein occlusion ( RVO ) due chorioidal neovascularization follow pathologic myopia ( mCNV ) repeat intravitreal injection Lucentis® ( Ranibizumab ) include optional OCT monitor 24 month observational period real life condition .</brief_summary>
	<brief_title>Observation Treatment Patterns With Lucentis Approved Indications</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Inclusion criterion : Presence neovascular ( wet ) agerelated macular degeneration ( AMD ) , visual impairment due diabetic macular oedema ( DME ) , visual impairment due macular oedema secondary retinal vein occlusion ( branch RVO central RVO ) visual impairment due choroidal neovascularisation ( CNV ) secondary pathologic myopia ( PM ) Patients therapy Lucentis® medically indicate . Written patient informed consent . Exclusion criterion : As describe SmPC . Preceding intravitreal treatment study eye antiVEGF drug last three month enrollment Preceding intravitreal treatment study eye steroid</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>